Wells Fargo & Company MN lifted its stake in shares of MEDNAX Inc (NYSE:MD) by 4.0% in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 393,514 shares of the company’s stock after buying an additional 14,973 shares during the quarter. Wells Fargo & Company MN owned approximately 0.47% of MEDNAX worth $9,929,000 as of its most recent filing with the Securities and Exchange Commission.
Other hedge funds also recently added to or reduced their stakes in the company. Lazard Asset Management LLC raised its stake in shares of MEDNAX by 150.5% during the first quarter. Lazard Asset Management LLC now owns 1,390,670 shares of the company’s stock valued at $37,784,000 after purchasing an additional 835,444 shares in the last quarter. Nordea Investment Management AB raised its position in MEDNAX by 41.5% in the first quarter. Nordea Investment Management AB now owns 2,411,506 shares of the company’s stock worth $65,521,000 after acquiring an additional 707,038 shares in the last quarter. First Trust Advisors LP raised its position in MEDNAX by 40.8% in the first quarter. First Trust Advisors LP now owns 1,457,639 shares of the company’s stock worth $39,604,000 after acquiring an additional 422,706 shares in the last quarter. Dimensional Fund Advisors LP raised its position in MEDNAX by 17.1% in the fourth quarter. Dimensional Fund Advisors LP now owns 2,615,192 shares of the company’s stock worth $86,301,000 after acquiring an additional 381,394 shares in the last quarter. Finally, WINTON GROUP Ltd raised its position in MEDNAX by 79.6% in the second quarter. WINTON GROUP Ltd now owns 802,412 shares of the company’s stock worth $20,245,000 after acquiring an additional 355,681 shares in the last quarter. 92.30% of the stock is owned by institutional investors and hedge funds.
Several brokerages have commented on MD. UBS Group dropped their price target on shares of MEDNAX to $20.00 and set a “sell” rating on the stock in a research report on Wednesday, July 24th. BMO Capital Markets dropped their price target on shares of MEDNAX from $32.00 to $25.00 and set a “market perform” rating on the stock in a research report on Monday, August 5th. Mizuho dropped their price target on shares of MEDNAX from $26.00 to $24.00 and set a “neutral” rating on the stock in a research report on Friday, August 2nd. Zacks Investment Research cut shares of MEDNAX from a “hold” rating to a “sell” rating and set a $26.00 price target on the stock. in a research report on Wednesday, July 3rd. Finally, Bank of America cut shares of MEDNAX from a “neutral” rating to an “underperform” rating and set a $19.00 price target on the stock. in a research report on Friday, September 6th. Four research analysts have rated the stock with a sell rating, five have issued a hold rating and three have assigned a buy rating to the stock. MEDNAX has a consensus rating of “Hold” and a consensus price target of $28.30.
MD traded down $0.51 during trading on Thursday, reaching $23.15. The company had a trading volume of 20,627 shares, compared to its average volume of 1,018,658. The firm’s 50-day simple moving average is $21.95 and its 200 day simple moving average is $26.03. The company has a market cap of $1.89 billion, a price-to-earnings ratio of 6.58, a PEG ratio of 0.87 and a beta of 0.73. MEDNAX Inc has a 12-month low of $19.93 and a 12-month high of $48.77. The company has a debt-to-equity ratio of 0.79, a quick ratio of 2.23 and a current ratio of 2.23.
MEDNAX (NYSE:MD) last released its earnings results on Thursday, August 1st. The company reported $0.89 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.78 by $0.11. MEDNAX had a positive return on equity of 9.34% and a negative net margin of 3.53%. The company had revenue of $868.31 million for the quarter, compared to analysts’ expectations of $868.71 million. During the same quarter in the previous year, the business posted $1.07 EPS. The business’s revenue for the quarter was up .4% on a year-over-year basis. On average, sell-side analysts expect that MEDNAX Inc will post 3.04 EPS for the current year.
MEDNAX, Inc, together with its subsidiaries, provides newborn, anesthesia, maternal-fetal, radiology and teleradiology, pediatric cardiology, and other pediatric subspecialty physician services in the United States and Puerto Rico. It offers neonatal care services, such as clinical care to babies born prematurely or with complications within specific units at hospitals through neonatal physician subspecialists, neonatal nurse practitioners, and other pediatric clinicians; anesthesia and anesthesia subspecialty care services; and acute and chronic pain management services.
Featured Article: What is a capital gains distribution?
Want to see what other hedge funds are holding MD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for MEDNAX Inc (NYSE:MD).
Receive News & Ratings for MEDNAX Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MEDNAX and related companies with MarketBeat.com's FREE daily email newsletter.